+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis



Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis



Artificial Organs 25(12): 967-973



The purpose of this study was to compare the efficacy of high-dose intravenous immunoglobulin (IVIG) treatment with plasma exchange in patients suffering from moderate to severe myasthenia gravis (MG) in a stable phase. There are no controlled studies comparing IVIG with plasma exchange in patients who despite immunosuppressive treatment have persistent incapacitating MG symptoms. This was a controlled crossover study. Twelve patients with generalized moderate to severe MG on immunosuppressive treatment for at least 12 months were included. The patients were evaluated clinically using a quantified MG clinical score (QMGS) before and at follow-up visits after each treatment. One week after the treatments, the patients who received plasma exchange treatment showed a significant improvement in QMGS compared to baseline but although some improvement was seen after IVIG this did not reach statistical significance. Four weeks after both plasma exchange and IVIG treatments, there was a significant improvement in QMGS compared to baseline. One week and 4 weeks after treatment, no significant difference between the 2 treatments was found. Both treatments have a clinically significant effect 4 weeks out in patients with chronic MG, but the improvement has a more rapid onset after plasma exchange than after IVIG.

(PDF emailed within 0-6 h: $19.90)

Accession: 010796414

Download citation: RISBibTeXText

DOI: 10.1046/j.1525-1594.2001.06717.x


Related references

Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artificial Organs 25(12): 967-973, 2002

Clinical effect of high-dose intravenous immunoglobulin compared to plasma exchange in patients with moderate to severe myasthenia gravis. Neurology 52(6 SUPPL 2): A184-A185, April 12, 1999

Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up. Therapeutic Apheresis and Dialysis 13(3): 174-178, 2009

Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. Journal of Clinical Neuromuscular Disease 13(2): 85-94, 2012

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Annals of Neurology 41(6): 789-796, 1997

Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial. Journal of Neurology 254(8): 989-995, 2007

Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle and Nerve 53(6): 872-876, 2017

Plasma exchange, tryptophan and protein A columns adsorption in the treatment of a severe Myasthenia Gravis patient. Transfusion Science 14(4): 369-370, 1993

Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Annals of the New York Academy of Sciences 841: 720-726, 1998

Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab. Pediatric Blood and Cancer 61(5): 928-930, 2014

Plasma exchange in severe myasthenia gravis. Clinical Science & Molecular Medicine 52(2): 11P, 1977

A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. Journal of Clinical Neuromuscular Disease 9(3): 352-355, 2008

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Annals Of Neurology. 41(6): 789-796, 1997

Plasma exchange therapy for severe penicillamine-induced myasthenia gravis. Journal of Rheumatology 8(2): 303-307, 1981

A short plasma exchange protocol is effective in severe myasthenia gravis. Journal of Neurology 238(2): 103-107, 1991